ライフサイエンスコーパス: fructosamine

1 ng form aldohexoses showed ions identical to fructosamine.

2 tions in the level of the deglycating enzyme fructosamine-3-kinase (FN3K) might be associated with th

3 fication and characterization of a mammalian fructosamine-3-kinase (FN3K), which phosphorylates fruct

4 incident diabetes were 4.96 (4.36-5.64) for fructosamine above the 95th percentile and 6.17 (5.45-6.

5 xidative deglycation of low molecular weight fructosamines (Amadori products).

6 ariable-adjusted HRs for CKD for people with fructosamine and glycated albumin above the 95th percent

7 Fructosamine and glycated albumin are markers of short-t

8 Fructosamine and glycated albumin are markers of short-t

9 as by HbA1c (0.726), but HbA1c outperformed fructosamine and glycated albumin for prediction of inci

10 Our aim was to clarify the performance of fructosamine and glycated albumin measurements for ident

11 We found that fructosamine and glycated albumin were associated with v

12 Elevated baseline concentrations of fructosamine and glycated albumin were significantly ass

13 Fructosamine and glycated albumin were strongly associat

14 Fructosamine and glycated albumin were strongly associat

15 We evaluated associations of fructosamine and glycated albumin with risk of coronary

16 We assessed the associations of fructosamine and glycated albumin with risk of incident

17 black and white persons in glycated albumin, fructosamine, and 1,5-anhydroglucitol levels parallel di

18 blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostasis Model Assessment-Insulin R

19 A1C, fructosamine, and in vitro determination of the (14)C-3O

20 ght GH, plasma glucose, free insulin, IGF-I, fructosamine, and lipid profiles were assessed during th

21 ds, colorimetric assay using capillary blood fructosamine as a reference molecule was used.

22 Fructosamine assays were performed blinded to vital stat

23 Prediction of incident CKD by fructosamine (C statistic 0.717) and glycated albumin (0

24 umption (P < 0.01, effect of sugar), whereas fructosamine concentrations did not differ between group

25 iles and fasting plasma glycated albumin and fructosamine concentrations were measured 0, 2, 8, and 1

26 After 19 days of rhIGF-I treatment, fructosamine concentrations were unchanged compared with

27 ein, glucose, glycated hemoglobin A(1c), and fructosamine concentrations; insulin sensitivity; and gl

28 Fructosamine declined from 369 to 299 mumol/l by 3 weeks

29 asting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable f

30 e combination treatment reduced the elevated fructosamine, glycated hemoglobin, and advanced glycatio

31 We measured glycated albumin and fructosamine in 11 104 participants with and without dia

32 We measured glycated albumin and fructosamine in blood samples from 11 348 adults without

33 rades Amadori products oxidatively into free fructosamine, is classified as fructosyl aminocaproate:o

34 R] per 1 SD [1.4 kg], 2.4; 95% CI, 1.6-3.7), fructosamine level (OR per 1 SD [1.1 mumol/L], 2.0; 95%

35 standard deviation (46 micromol) increase in fructosamine level was associated with a 1.3-fold (95% c

36 Fructosamine level, or another indicator of glycemia, sh

37 Elevated fructosamine levels (>285 micromol/liter) were associate

38 Serum fructosamine levels can be used to estimate long-term se

39 cantly higher HbA(1c), glycated albumin, and fructosamine levels than white persons before and after

40 The authors examined whether fructosamine levels were associated with mortality in a

41 Likewise, changes in fasting glucose and fructosamine levels were similar.

42 in the relationship of glycated albumin and fructosamine levels with the mean glucose concentration

43 , plasma concentrations of glucose, insulin, fructosamine, lipase, amylase, and TNF-alpha were increa

44 ) plasma concentrations of glucose, insulin, fructosamine, lipase, amylase, and tumor necrosis factor

45 creening test in detecting IFG/IGT or NODAT, fructosamine may be a more accurate diagnostic test but

46 hereas Amadori products were assessed by the fructosamine method.

47 ass; levels of fasting glucose, insulin, and fructosamine; older age; nonwhite race; family history o

48 en compared with people with no diabetes and fructosamine or glycated albumin below the 75th percenti

49 xidative deglycation of low molecular weight fructosamines or Amadori products.

50 diabetic control (fasting plasma glucose or fructosamine) or by any change in the plasma levels of k

51 Fructosamine oxidase has a lysine near N5 of its flavin.

52 Fructosamine oxidases (FAOX) catalyze the oxidative degl

53 Fructosamine oxidases (FAOXs) are flavin-containing enzy

54 The use of fructosamine oxidases, (Faox) provided promising results

55 The fructosamine substrate is oxidized by the flavin in the

56 Key early intermediates in this process are fructosamines, such as protein-bound fructoselysines.

57 -to-C(o) ratio was not correlated with serum fructosamine, suggesting that it was independent of mean

58 comparison with glycation of serum proteins (fructosamine), the glycation gap.

59 howed that fasting blood glucose, C-peptide, fructosamine, triglyceride and free fatty acid contents

60 ed by race with HbA1c, glycated albumin, and fructosamine values.

61 deglycates amino acids under release of free fructosamine was isolated.

62 2-hour oral glucose tolerance test (n = 66), fructosamine was the most accurate diagnostic test with

63 5% confidence interval [95% CI], 0.77-0.93), fructosamine was the most accurate test with adjusted AU

64 d Lys-368 bind the carboxylic portion of the fructosamine, whereas Glu-280 and Arg-411 bind the fruct

65 ctivity of FAOX enzymes toward protein-bound fructosamines, which would have difficulty accessing the